Capricor Therapeutics to Report Second Quarter 2026 Financial Results and Provide Recent Corporate Update on August 13
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) will release its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, August 13, 2026. Management will host a conference call and webcast at 4:30 p.m. ET the same day to discuss results and provide a recent corporate update.
The call can be accessed via toll-free and international dial-in numbers using Conference ID 91880, or through a webcast link. A replay will be available shortly after in the Investors section of Capricor’s website. Capricor’s lead candidate, Deramiocel, is in late-stage development for Duchenne muscular dystrophy, and the company is also advancing its StealthX™ exosome platform.
Positive
- None.
Negative
- None.
Market reaction after 2Q26 earnings report: CAPR -6.19%
Following this news, CAPR has declined 6.19%, reflecting a notable negative market reaction. Our momentum scanner has triggered 17 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $3.84.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | Earnings date | Neutral | -1.6% | Scheduled first-quarter results release and conference call announcement |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific record shows the prior earnings-date announcement was followed by a -1.61% 24-hour reaction.
Key Terms
exosome-based therapeutics medical
allogeneic medical
oligonucleotides medical
Duchenne muscular dystrophy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Company to Host Conference Call on August 13, 2026, at 4:30 p.m. ET –
SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the second quarter ended June 30, 2026, after the market close on Thursday, August 13, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.
| Title: | Capricor Therapeutics Second Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast |
| Date: | Thursday, August 13, 2026 |
| Time: | 4:30 p.m. ET |
| Call Details: | Toll-Free: 1-800-717-1738 International: 1-646-307-1865 Conference ID: 91880 Participants may dial in using the numbers above and ask to be joined to the call, or use the Call me™ link for instant telephone access to the event. |
| Webcast: | Click here |
A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company’s website at www.capricor.com.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), shown in clinical studies to preserve cardiac and skeletal muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit capricor.com, and follow Capricor on Facebook, Instagram and X.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, revenue and reimbursement estimates, projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources, and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as filed with the Securities and Exchange Commission on May 13, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com / rcona@kcsa.com
212.896.1241 / 516.779.2630
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
